Symposium
Lowell S. Kabnick, MD, FACS (he/him/his)
Chancellor
Vein and Lymphatic University
Far Hills, New Jersey, United States
Disclosure(s): Amsel: Consultant/Advisory Board, Ownership Interest, Research Grant; AngioDynamics: Consultant/Advisory Board, Ownership Interest, Royalties, Speaker/Honoraria; BD/BARD: Research Grant, Speaker/Honoraria; Boston Scientific: Research Grant, Speaker/Honoraria; Venari: Ownership Interest, Speaker/Honoraria
Victor Canata, MD (Prof Dr Fpsp Rvt)
Professor Doctor
Centro Paraguayo De Varices/ Universidad Nacional De Asuncion
Universidad nacional de asuncion facultad de medicina
Riverview, FL, United States
Disclosure(s):
The forementioned Program Planner, Faculty, Author, Moderator, or Speaker, has declared for this educational activity, having no relevant financial relationship(s) with ineligible companies to disclose. or AVLS has reviewed / mitigated there are no relevant financial relationships with ineligible companies.
Efthymios Makis Avgerinos, MD
Prof. of Vascular Surgery
Athens Medical Center, University of Athens
Athens, Attiki, Greece
Disclosure(s): BD Medical: Speaker/Honoraria; Bentley: Speaker/Honoraria; Boston Scientific: Speaker/Honoraria; Gore Medical: Speaker/Honoraria; INARI Medical: Speaker/Honoraria; Philips: Speaker/Honoraria; Servier: Speaker/Honoraria; Think Sono: Speaker/Honoraria
Manj Gohel, MD FRCS FEBVS
Consultant Vascular Surgeon
Cambridge University Hospitals
Imperial College London
Cambridge, England, United Kingdom
Disclosure(s): BD: Consultant/Advisory Board, Speaker/Honoraria; Cook Medical: Consultant/Advisory Board, Speaker/Honoraria; Gore Medical: Research Grant; Medtronic: Consultant/Advisory Board, Other Research Support, Research Grant, Speaker/Honoraria
Satish Vayuvegula, MD, MS, FAVLS (he/him/his)
President-Elect AVLS
AVLS
Carrollton, TX, United States
Disclosure(s):
The forementioned Program Planner, Faculty, Author, Moderator, or Speaker, has declared for this educational activity, having no relevant financial relationship(s) with ineligible companies to disclose. or AVLS has reviewed / mitigated there are no relevant financial relationships with ineligible companies.